Back to search
FDAFDA · Food and drugs·Recall number D-0813-2026

CARDENE IV (Nicardipine Hydrochloride) in 0.83% Sodium Chloride Injection, 40 mg in 200 mL (0.2 mg/mL) in GALAXY Single-Dose Container, Manufactured and Marketed by: Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 43066-016-10.

Published September 9, 2026 · Recall initiated: August 6, 2026

Summary

FDA records drug Class II recall D-0813-2026, published September 9, 2026 and initiated August 6, 2026. Recalling firm: Baxter Healthcare Corporation; Status: Ongoing; Reported quantity: N/A; Lot: Lot # NC177818, Exp Date: 12/31/2026; Lot # NC188869, Exp Date: 12/31/2027. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations

What to do

Voluntary: Firm initiated · Letter

Get an email if CARDENE IV has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
CARDENE IV
Manufacturer
Baxter Healthcare Corporation
Distributor
US Nationwide; Puerto Rico; and Chile.
Lot
Lot # NC177818, Exp Date: 12/31/2026; Lot # NC188869, Exp Date: 12/31/2027.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was CARDENE IV (Nicardipine Hydrochloride) in 0.83% Sodium Chloride Injection, 40 mg in 200 mL (0.2 mg/mL) in GALAXY Single-Dose Container, Manufactured and Marketed by: Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 43066-016-10. recalled?

Yes. FDA published recall D-0813-2026 on September 9, 2026. Reported hazard: CGMP Deviations

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: CARDENE IV.